ArticleFrontiers in immunology2019

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.

Roger H Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.